Literature DB >> 6476045

Perfluoropropane gas in the management of proliferative vitreoretinopathy.

S Chang, D J Coleman, H Lincoff, L M Wilcox, R A Braunstein, J M Maisel.   

Abstract

Perfluoropropane (C3F8), an expanding fluorinated hydrocarbon gas, was used as an adjunct to vitreous surgery in the management of 18 patients with retinal detachment complicated by proliferative vitreoretinopathy. Ten patients had reattached retinas six months after disappearance of the gas. The average intraocular longevity of the gas in successful cases was 92 days; that in failed cases was 62.7 days. This difference was not statistically significant. However, internal retinal tamponade by longer-lasting gases appears to increase the rate of retinal reattachment in the surgical management of proliferative vitreoretinopathy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6476045     DOI: 10.1016/0002-9394(87)90353-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Alterations in rabbit vitreal fine structure following C3F8 injection.

Authors:  B Panessa-Warren; J M Maisel; J Warren
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

2.  Intraoperative use of pure perfluoropropane gas in the management of proliferative vitreoretinopathy.

Authors:  M Bonnet; E Santamaria; J Mouche
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

3.  Randomized clinical trial of intraocular silicone vs. gas in the management of complicated retinal detachment and vitreous hemorrhage.

Authors:  G A Peyman; G W Kao; L R de Corral
Journal:  Int Ophthalmol       Date:  1987-08       Impact factor: 2.031

4.  Silicone-oil injection during closed microsurgery for diabetic retinal detachment.

Authors:  D McLeod
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

5.  Extended retinal tamponade in the treatment of retinal detachment with proliferative vitreoretinopathy.

Authors:  W H Stern; R N Johnson; A R Irvine; M E Barricks; B S Boyden; G F Hilton; L I Lonn; A Schwartz
Journal:  Br J Ophthalmol       Date:  1986-12       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.